Rhythm Pharmaceuticals (RYTM) PT Lowered to $152 at Citizens on 'Disappointing' Phase 3 EMANATE Trial
Tweet Send to a Friend
Citizens analyst Jonathan Wolleben lowered the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $152.00 (from $176.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
